Next Meetings

Atopic Dermatitis

Midwest CEPAC
May 25, 2017 10AM-4PM (CT)

University of Chicago Gleacher Center at the Booth School of Business
450 N Cityfront Plaza Drive
Chicago, IL 60611

The Midwest CEPAC will convene in May 2017 to discuss ICER's report on treatments for atopic dermatitis.

Register or Register for the Live Webcast

May 31, 2017

Kaiser Permanente Center for Total Health
700 2nd St NE, Washington, DC 20002
Washington, DC

ICER will host a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit will include discussion of how these methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system to allow for broader insurance coverage for innovative new treatments.

More information about the summit is available in a recent press release.

Register or Register for the Live Webcast

June 30, 2017

The California Endowment Los Angeles Conference Center
1000 N. Alameda St.
Los Angeles, CA, 90012

The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.


Abuse-Deterrent Opioids

New England CEPAC

ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.


Ovarian Cancer

Midwest CEPAC
September 14, 2017 10AM-4PM (CT)

Midwest, TBD

The Midwest CEPAC will convene to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.


October 19, 2017 TBD

California TBD

ICER will review evidence on the comparative clinical effectiveness and value of certain cognitive and mind-body interventions for chronic low back and neck pain.


Tardive Dyskinesia

New England CEPAC
December 5, 2017 10am-4pm ET

past Meetings

Jun 2016
CTAF

Diabetes Prevention Programs

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in June 2016 to discuss the comparative effectiveness and value of diabetes prevention programs.


Feb 2016
CTAF

Insulin Degludec (Tresiba®, Novo Nordisk) for Diabetes

The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.


Feb 2016
CTAF

Mepolizumab (Nucala®, GlaxoSmithKline) for Asthma

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in February 2016 to discuss a drug for patients with severe eosinophilic asthma. The asthma drug, mepolizumab (Nucala®, GlaxoSmithKline), is a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5).